ASX RELEASE 11 September 2026 Drawdown of Tranche 4 under the Convertible Note Facility Paradigm Biopharmaceuticals Ltd. (ASX: PAR) (“Paradigm” or “the Company”) a late-stage drug development company...
Drawdown of Tranche 4 under the Convertible Note Facility
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Application for quotation of securities - PAR
- Melbourne Investor Lunch
- Appendix 4E and 2026 Annual Report
- Appendix 4G and Corporate Governance Statement
- 80% Safety Review Complete, September IA on Track
Later from Paradigm Biopharmaceuticals
- Notification regarding unquoted securities - PAR
- Notice under Section 708A
- Dr Daniel Furtner appointed Chief Medical Officer
- Trading Halt
- Suspension from Quotation
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals